Mineralys Therapeutics, Inc. - Common Stock (NQ:MLYS)

23.44 -0.19 (-0.80%)

Delayed Quote Updated: 3:41 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mineralys Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Mineralys (MLYS) Q2 2026 Earnings Call Transcript ↗

August 18, 2026

Lorundrostat advances toward December FDA decision as company ramps commercial launch.

Via The Motley Fool

Topics Earnings

Mineralys Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider...

Via MarketBeat

Topics Earnings Initial Public Offering

A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date ↗

July 16, 2026

This executive exercised 20,407 options at $1.08 and immediately sold them at $27.28 per share.

Via The Motley Fool

Topics Regulatory Compliance

Mineralys Therapeutics Inc (NASDAQ:MLYS) First Quarter 2026 Results Show Modest Market Reaction to FDA NDA Acceptance ↗

May 06, 2026

Via Chartmill

Mineralys Therapeutics Inc (NASDAQ:MLYS) Reports Q4 2025 EPS Beat and Key FDA NDA Acceptance for Lorundrostat ↗

March 12, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

What to Know About This Mineralys Insider Sale Before a December FDA Date ↗

July 16, 2026

Insider divested 2% of direct holdings via pre-planned Rule 10b5-1 trading arrangement, following a 90% stock surge over the past year.

Via The Motley Fool

Topics Regulatory Compliance

What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision ↗

June 23, 2026

This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗

May 31, 2026

Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Mineralys (MLYS) Q1 2026 Earnings Transcript ↗

May 06, 2026

Mineralys (MLYS) Q1 2026 Earnings Transcript

Via The Motley Fool

Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? ↗

April 07, 2026

This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings.

Via The Motley Fool

Topics Regulatory Compliance

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Via The Motley Fool

Topics Regulatory Compliance

Mineralys (MLYS) Q4 2025 Earnings Call Transcript ↗

March 12, 2026

Mineralys (MLYS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗

December 23, 2025

When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys ↗

November 27, 2025

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

Via The Motley Fool

Topics Regulatory Compliance

MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate ↗

November 10, 2025

Mineralys Therapeutics beat Q3 2025 EPS estimates. The biotech firm is advancing its lead drug, lorundrostat, toward a planned FDA submission.

Via Chartmill

Uncovering Potential: Mineralys Therapeutics's Earnings Preview ↗

November 07, 2025

Via Benzinga

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗

September 21, 2025

Here's what needs to happen for these high flyers to continue soaring.

Via The Motley Fool

It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps ↗

September 16, 2025

A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one...

Via The Motley Fool

Topics Economy Stocks

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗

September 07, 2025

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Via The Motley Fool

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 03, 2025

Via Benzinga

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

September 03, 2025

Via Benzinga

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Nasdaq Down 1%; Signet Jewelers Earnings Top Views ↗

September 02, 2025

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.